Position in NTLA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$5,710,028
+$2,874,582 QoQ
Shares Held
445,400
+41.2% QoQ
Ownership
0.319%
of shares outstanding
% of Portfolio
3.99%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in NTLA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Birchview Capital, LP holds $86,547,277 across 48 Biotechnology names. NTLA ranks #3 (6.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CMPX |
Compass Therapeutics, Inc.
|
1,465,867 | $7,754,436 | |
| 2 | STOK |
Stoke Therapeutics, Inc.
|
210,000 | $6,837,600 | |
| 3 | NTLA |
Intellia Therapeutics, Inc.
This page
|
445,400 | $5,710,028 | |
| 4 | GPCR |
Structure Therapeutics Inc.
|
100,000 | $4,820,000 | |
| 5 | SLDB |
Solid Biosciences Inc.
|
625,980 | $4,507,056 | |
| 6 | PRTA |
Prothena Corp Public Ltd Co
|
449,019 | $4,364,464 | |
| 7 | ACAD |
Acadia Pharmaceuticals Inc
|
171,000 | $3,806,460 | |
| 8 | PTGX |
Protagonist Therapeutics, Inc
|
35,000 | $3,689,000 |
All Filings in NTLA
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,710,028 | 445,400 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $2,835,446 | 315,400 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,036,200 | 60,000 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $562,800 | 60,000 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||